Podcasts about pacific edge

Our hosts, Devin Griffiths and Deanna Kreisel, sat down with Dominic Boyer to talk about his new book, No More Fossils, which appeared just last year (2023) from the University of Minnesota's "Forerunners" series. We talked at length about his book, its gestation in basic questions about how to divest from fossil energy and fossil culture, and the grounds for optimism about our future. In a wide ranging discussion, we also talked about utopia, our investment in memoir and place-based writing, the importance of affect and anxiety in thinking about climate, and the fiction, scholarship, and activism that gives us inspiration.  Some show notes: we talked about other work by Dominic (including his books Hyposubjects and Energopolitics); other works on energy and ecocriticism (including Patricia Jaeger's column "Literature in the Ages of Wood, Tallow, Coal, Whale Oil, Gasoline, Atomic Power, and Other Energy Sources"; Cara New Dagget's The Birth of Energy; Allen MacDuffie's Victorian Literature, Energy, and the Ecological Imagination; and Heidi Scott's Fuel: An Ecocritical History; and Barbara Leckie's Climate Change: Interrupted); talked about matriarchal collectives and the show Station Eleven; and fiction including Kim Stanley Robinson's Pacific Edge, and Edward Bellamy's Looking Backward; and William Morris's News from Nowhere; and finally, Osaka University's "Fragmentary Institute of Comparative Timelines," and Troy Vettese and Drew Pendergrass's book, Half-Earth Socialism: A Plan to Save the Future from Extinction, Climate Change, and Pandemics. It was awesome. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/science-technology-and-society

Our hosts, Devin Griffiths and Deanna Kreisel, sat down with Dominic Boyer to talk about his new book, No More Fossils, which appeared just last year (2023) from the University of Minnesota's "Forerunners" series. We talked at length about his book, its gestation in basic questions about how to divest from fossil energy and fossil culture, and the grounds for optimism about our future. In a wide ranging discussion, we also talked about utopia, our investment in memoir and place-based writing, the importance of affect and anxiety in thinking about climate, and the fiction, scholarship, and activism that gives us inspiration.  Some show notes: we talked about other work by Dominic (including his books Hyposubjects and Energopolitics); other works on energy and ecocriticism (including Patricia Jaeger's column "Literature in the Ages of Wood, Tallow, Coal, Whale Oil, Gasoline, Atomic Power, and Other Energy Sources"; Cara New Dagget's The Birth of Energy; Allen MacDuffie's Victorian Literature, Energy, and the Ecological Imagination; and Heidi Scott's Fuel: An Ecocritical History; and Barbara Leckie's Climate Change: Interrupted); talked about matriarchal collectives and the show Station Eleven; and fiction including Kim Stanley Robinson's Pacific Edge, and Edward Bellamy's Looking Backward; and William Morris's News from Nowhere; and finally, Osaka University's "Fragmentary Institute of Comparative Timelines," and Troy Vettese and Drew Pendergrass's book, Half-Earth Socialism: A Plan to Save the Future from Extinction, Climate Change, and Pandemics. It was awesome. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/critical-theory

Our hosts, Devin Griffiths and Deanna Kreisel, sat down with Dominic Boyer to talk about his new book, No More Fossils, which appeared just last year (2023) from the University of Minnesota's "Forerunners" series. We talked at length about his book, its gestation in basic questions about how to divest from fossil energy and fossil culture, and the grounds for optimism about our future. In a wide ranging discussion, we also talked about utopia, our investment in memoir and place-based writing, the importance of affect and anxiety in thinking about climate, and the fiction, scholarship, and activism that gives us inspiration.  Some show notes: we talked about other work by Dominic (including his books Hyposubjects and Energopolitics); other works on energy and ecocriticism (including Patricia Jaeger's column "Literature in the Ages of Wood, Tallow, Coal, Whale Oil, Gasoline, Atomic Power, and Other Energy Sources"; Cara New Dagget's The Birth of Energy; Allen MacDuffie's Victorian Literature, Energy, and the Ecological Imagination; and Heidi Scott's Fuel: An Ecocritical History; and Barbara Leckie's Climate Change: Interrupted); talked about matriarchal collectives and the show Station Eleven; and fiction including Kim Stanley Robinson's Pacific Edge, and Edward Bellamy's Looking Backward; and William Morris's News from Nowhere; and finally, Osaka University's "Fragmentary Institute of Comparative Timelines," and Troy Vettese and Drew Pendergrass's book, Half-Earth Socialism: A Plan to Save the Future from Extinction, Climate Change, and Pandemics. It was awesome. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/anthropology

Our hosts, Devin Griffiths and Deanna Kreisel, sat down with Dominic Boyer to talk about his new book, No More Fossils, which appeared just last year (2023) from the University of Minnesota's "Forerunners" series. We talked at length about his book, its gestation in basic questions about how to divest from fossil energy and fossil culture, and the grounds for optimism about our future. In a wide ranging discussion, we also talked about utopia, our investment in memoir and place-based writing, the importance of affect and anxiety in thinking about climate, and the fiction, scholarship, and activism that gives us inspiration.  Some show notes: we talked about other work by Dominic (including his books Hyposubjects and Energopolitics); other works on energy and ecocriticism (including Patricia Jaeger's column "Literature in the Ages of Wood, Tallow, Coal, Whale Oil, Gasoline, Atomic Power, and Other Energy Sources"; Cara New Dagget's The Birth of Energy; Allen MacDuffie's Victorian Literature, Energy, and the Ecological Imagination; and Heidi Scott's Fuel: An Ecocritical History; and Barbara Leckie's Climate Change: Interrupted); talked about matriarchal collectives and the show Station Eleven; and fiction including Kim Stanley Robinson's Pacific Edge, and Edward Bellamy's Looking Backward; and William Morris's News from Nowhere; and finally, Osaka University's "Fragmentary Institute of Comparative Timelines," and Troy Vettese and Drew Pendergrass's book, Half-Earth Socialism: A Plan to Save the Future from Extinction, Climate Change, and Pandemics. It was awesome. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/environmental-studies

Our hosts, Devin Griffiths and Deanna Kreisel, sat down with Dominic Boyer to talk about his new book, No More Fossils, which appeared just last year (2023) from the University of Minnesota's "Forerunners" series. We talked at length about his book, its gestation in basic questions about how to divest from fossil energy and fossil culture, and the grounds for optimism about our future. In a wide ranging discussion, we also talked about utopia, our investment in memoir and place-based writing, the importance of affect and anxiety in thinking about climate, and the fiction, scholarship, and activism that gives us inspiration.  Some show notes: we talked about other work by Dominic (including his books Hyposubjects and Energopolitics); other works on energy and ecocriticism (including Patricia Jaeger's column "Literature in the Ages of Wood, Tallow, Coal, Whale Oil, Gasoline, Atomic Power, and Other Energy Sources"; Cara New Dagget's The Birth of Energy; Allen MacDuffie's Victorian Literature, Energy, and the Ecological Imagination; and Heidi Scott's Fuel: An Ecocritical History; and Barbara Leckie's Climate Change: Interrupted); talked about matriarchal collectives and the show Station Eleven; and fiction including Kim Stanley Robinson's Pacific Edge, and Edward Bellamy's Looking Backward; and William Morris's News from Nowhere; and finally, Osaka University's "Fragmentary Institute of Comparative Timelines," and Troy Vettese and Drew Pendergrass's book, Half-Earth Socialism: A Plan to Save the Future from Extinction, Climate Change, and Pandemics. It was awesome. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

Harvey Brownstone conducts an in-depth Interview with Barbara Bain, Legendary Actress, “Mission Impossible” About Harvey's guest: Today's special guest, Barbara Bain, is a beloved actress who is perhaps best known for her portrayal of undercover agent “Cinnamon Carter” on the classic TV series, “Mission: Impossible”, for which she became the first actress in television history to receive 3 consecutive Emmy Awards for Outstanding Lead Actress in a Drama Series.   She also received a Golden Globe Award nomination and a Photoplay Award nomination for Best Female TV star.  She also created the iconic role of “Dr. Helena Russell” in the classic British science fiction series “Space: 1999” and the made-for-TV movies “Alien Attack”, “Destination Moonbase Alpha”, “Cosmic Princess” and “Journey Through the Black Sun”.    And over the years we've seen her in dozens of TV shows including “The Dick Van Dyke Show”, “Perry Mason”, “Get Smart”, “Moonlighting”, “Murder, She Wrote”, “Diagnosis Murder”, “CSI” and many more.  Her movie credits include “Savage”, “Skinheads”, “Panic”, “Bel Air”, “Trapped”, “Political Disasters”, “Nothing Special”, “On the Rocks”,  “American Gun”, for which she received a DVD Exclusive Award nomination for Best Supporting Actress, and 3 of my favourite  short films: “Reconnected”, for which she received a Best Actress nomination at the Madrid International Film Festival; “Take My Hand”, for which she won 3 prestigious film festival awards; and “Pacific Edge”, for which she won Best Actress Awards at the Golden Door International Film Festival AND the Los Angeles Independent Film Festival.   And I can't resist mentioning her hilarious performance as “Dr. Olga Schmetner” in the 1981 TV movie, “The Harlem Globetrotters on Gilligan's Island”.    On the stage, she's won Los Angeles Critic's Circle and DramaLogue Awards for her performances in "Wings", "Happy Days" and "The Chairs".    And in 2016 she received a star on the Hollywood Walk of Fame.   And if ALL OF THAT weren't enough, out guest founded a children's literacy program through the Screen Actors Guild called "Book Pals", which initially had hundreds of actors reading to school children in major cities across America.  And now it's an online program called “Storyline Online”, so kids all over the world can choose a famous actor to read them a story. For more interviews and podcasts go to: https://www.harveybrownstoneinterviews.com/ To learn more about Barbara Bain, go to:https://twitter.com/thebarbarabain #BarbaraBain    #harveybrownstoneinterviews

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YRR865. CME/MOC/AAPA/IPCE credit will be available until February 25, 2025.Doing Better Under Pressure in Prostate Cancer: Key Evidence and Real-World Care Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Astellas and Pfizer, Inc., Bayer HealthCare Pharmaceuticals Inc., Exelixis, Inc., Lantheus Medical Imaging, and Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerRobert Dreicer, MD, MS, MACP, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas Pharma Inc.; Bayer Corporation; Exelixis, Inc.; Gilead Sciences, Inc.; Hinova; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer; Sanofi Genzyme; Seagen Inc.; and Tavanta Therapeutics.Faculty/PlannerAlicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Antev Ltd.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.Faculty/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Antev Ltd.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aura Biosciences, Inc.; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Cold Genesys Inc; Dendreon Pharmaceuticals LLC; Exact Imaging; F. Hoffmann-La Roche Ltd./Genentech, Inc.; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; GenesisCare; ImmunityBio, Inc.; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; PreView Medical, Inc.; ProFound Medical; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi Genzyme; Specialty Networks; Telix Pharmaceuticals Limited; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerMatthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ambrx; Astellas Pharma Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YRR865. CME/MOC/AAPA/IPCE credit will be available until February 25, 2025.Doing Better Under Pressure in Prostate Cancer: Key Evidence and Real-World Care Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Astellas and Pfizer, Inc., Bayer HealthCare Pharmaceuticals Inc., Exelixis, Inc., Lantheus Medical Imaging, and Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerRobert Dreicer, MD, MS, MACP, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas Pharma Inc.; Bayer Corporation; Exelixis, Inc.; Gilead Sciences, Inc.; Hinova; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer; Sanofi Genzyme; Seagen Inc.; and Tavanta Therapeutics.Faculty/PlannerAlicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Antev Ltd.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.Faculty/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Antev Ltd.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aura Biosciences, Inc.; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Cold Genesys Inc; Dendreon Pharmaceuticals LLC; Exact Imaging; F. Hoffmann-La Roche Ltd./Genentech, Inc.; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; GenesisCare; ImmunityBio, Inc.; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; PreView Medical, Inc.; ProFound Medical; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi Genzyme; Specialty Networks; Telix Pharmaceuticals Limited; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerMatthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ambrx; Astellas Pharma Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YRR865. CME/MOC/AAPA/IPCE credit will be available until February 25, 2025.Doing Better Under Pressure in Prostate Cancer: Key Evidence and Real-World Care Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Astellas and Pfizer, Inc., Bayer HealthCare Pharmaceuticals Inc., Exelixis, Inc., Lantheus Medical Imaging, and Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerRobert Dreicer, MD, MS, MACP, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas Pharma Inc.; Bayer Corporation; Exelixis, Inc.; Gilead Sciences, Inc.; Hinova; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer; Sanofi Genzyme; Seagen Inc.; and Tavanta Therapeutics.Faculty/PlannerAlicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Antev Ltd.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.Faculty/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Antev Ltd.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aura Biosciences, Inc.; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Cold Genesys Inc; Dendreon Pharmaceuticals LLC; Exact Imaging; F. Hoffmann-La Roche Ltd./Genentech, Inc.; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; GenesisCare; ImmunityBio, Inc.; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; PreView Medical, Inc.; ProFound Medical; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi Genzyme; Specialty Networks; Telix Pharmaceuticals Limited; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerMatthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ambrx; Astellas Pharma Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YRR865. CME/MOC/AAPA/IPCE credit will be available until February 25, 2025.Doing Better Under Pressure in Prostate Cancer: Key Evidence and Real-World Care Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Astellas and Pfizer, Inc., Bayer HealthCare Pharmaceuticals Inc., Exelixis, Inc., Lantheus Medical Imaging, and Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerRobert Dreicer, MD, MS, MACP, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas Pharma Inc.; Bayer Corporation; Exelixis, Inc.; Gilead Sciences, Inc.; Hinova; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer; Sanofi Genzyme; Seagen Inc.; and Tavanta Therapeutics.Faculty/PlannerAlicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Antev Ltd.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.Faculty/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Antev Ltd.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aura Biosciences, Inc.; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Cold Genesys Inc; Dendreon Pharmaceuticals LLC; Exact Imaging; F. Hoffmann-La Roche Ltd./Genentech, Inc.; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; GenesisCare; ImmunityBio, Inc.; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; PreView Medical, Inc.; ProFound Medical; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi Genzyme; Specialty Networks; Telix Pharmaceuticals Limited; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerMatthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ambrx; Astellas Pharma Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YRR865. CME/MOC/AAPA/IPCE credit will be available until February 25, 2025.Doing Better Under Pressure in Prostate Cancer: Key Evidence and Real-World Care Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Astellas and Pfizer, Inc., Bayer HealthCare Pharmaceuticals Inc., Exelixis, Inc., Lantheus Medical Imaging, and Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerRobert Dreicer, MD, MS, MACP, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas Pharma Inc.; Bayer Corporation; Exelixis, Inc.; Gilead Sciences, Inc.; Hinova; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer; Sanofi Genzyme; Seagen Inc.; and Tavanta Therapeutics.Faculty/PlannerAlicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Antev Ltd.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.Faculty/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Antev Ltd.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aura Biosciences, Inc.; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Cold Genesys Inc; Dendreon Pharmaceuticals LLC; Exact Imaging; F. Hoffmann-La Roche Ltd./Genentech, Inc.; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; GenesisCare; ImmunityBio, Inc.; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; PreView Medical, Inc.; ProFound Medical; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi Genzyme; Specialty Networks; Telix Pharmaceuticals Limited; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerMatthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ambrx; Astellas Pharma Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YRR865. CME/MOC/AAPA/IPCE credit will be available until February 25, 2025.Doing Better Under Pressure in Prostate Cancer: Key Evidence and Real-World Care Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Astellas and Pfizer, Inc., Bayer HealthCare Pharmaceuticals Inc., Exelixis, Inc., Lantheus Medical Imaging, and Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerRobert Dreicer, MD, MS, MACP, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas Pharma Inc.; Bayer Corporation; Exelixis, Inc.; Gilead Sciences, Inc.; Hinova; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer; Sanofi Genzyme; Seagen Inc.; and Tavanta Therapeutics.Faculty/PlannerAlicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Antev Ltd.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.Faculty/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Antev Ltd.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aura Biosciences, Inc.; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Cold Genesys Inc; Dendreon Pharmaceuticals LLC; Exact Imaging; F. Hoffmann-La Roche Ltd./Genentech, Inc.; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; GenesisCare; ImmunityBio, Inc.; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; PreView Medical, Inc.; ProFound Medical; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi Genzyme; Specialty Networks; Telix Pharmaceuticals Limited; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerMatthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ambrx; Astellas Pharma Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XJV865. CME/MOC/AAPA credit will be available until December 28, 2024.Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerSia Daneshmand, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ferring Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Pacific Edge; Pfizer; Photocure; Protara Therapeutics, Inc.; Sesen Bio (Carisma Therapeutics); TARIS Biomedical; and UroGen.Grant/Research Support from Janssen Pharmaceuticals, Inc.Faculty/PlannerGuru P. Sonpavde, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bicycle Therapeutics; Bristol Myers Squibb; EMD Serono Inc.; Ellipses Pharma; Exelixis, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Infinity Pharmaceuticals, Inc.; IMV Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; Lucence Health Inc.; Merck & Co., Inc.; Pfizer; PRECISCA; Sanofi; Scholar Rock; Seattle Genetics (Seagen Inc.)/Astellas Pharma Inc.; Servier Laboratories; SUBA THERAPEUTICS, INC.; Syapse; Syncorp Health; Tempus; and Vial.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; EMD Serono Inc.; Gilead Sciences, Inc.; Helsinn Healthcare SA; Jazz Pharmaceuticals; Lucence; and Sanofi. Research support to institution.Speaker for AVEO Pharmaceuticals, Inc.; Bayer Corporation; BIO Brazilian Information Oncology; Exelixis, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Natera, Inc.; OLE Forum (Mexico); and Seagen Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XJV865. CME/MOC/AAPA credit will be available until December 28, 2024.Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerSia Daneshmand, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ferring Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Pacific Edge; Pfizer; Photocure; Protara Therapeutics, Inc.; Sesen Bio (Carisma Therapeutics); TARIS Biomedical; and UroGen.Grant/Research Support from Janssen Pharmaceuticals, Inc.Faculty/PlannerGuru P. Sonpavde, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bicycle Therapeutics; Bristol Myers Squibb; EMD Serono Inc.; Ellipses Pharma; Exelixis, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Infinity Pharmaceuticals, Inc.; IMV Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; Lucence Health Inc.; Merck & Co., Inc.; Pfizer; PRECISCA; Sanofi; Scholar Rock; Seattle Genetics (Seagen Inc.)/Astellas Pharma Inc.; Servier Laboratories; SUBA THERAPEUTICS, INC.; Syapse; Syncorp Health; Tempus; and Vial.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; EMD Serono Inc.; Gilead Sciences, Inc.; Helsinn Healthcare SA; Jazz Pharmaceuticals; Lucence; and Sanofi. Research support to institution.Speaker for AVEO Pharmaceuticals, Inc.; Bayer Corporation; BIO Brazilian Information Oncology; Exelixis, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Natera, Inc.; OLE Forum (Mexico); and Seagen Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XJV865. CME/MOC/AAPA credit will be available until December 28, 2024.Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerSia Daneshmand, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ferring Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Pacific Edge; Pfizer; Photocure; Protara Therapeutics, Inc.; Sesen Bio (Carisma Therapeutics); TARIS Biomedical; and UroGen.Grant/Research Support from Janssen Pharmaceuticals, Inc.Faculty/PlannerGuru P. Sonpavde, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bicycle Therapeutics; Bristol Myers Squibb; EMD Serono Inc.; Ellipses Pharma; Exelixis, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Infinity Pharmaceuticals, Inc.; IMV Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; Lucence Health Inc.; Merck & Co., Inc.; Pfizer; PRECISCA; Sanofi; Scholar Rock; Seattle Genetics (Seagen Inc.)/Astellas Pharma Inc.; Servier Laboratories; SUBA THERAPEUTICS, INC.; Syapse; Syncorp Health; Tempus; and Vial.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; EMD Serono Inc.; Gilead Sciences, Inc.; Helsinn Healthcare SA; Jazz Pharmaceuticals; Lucence; and Sanofi. Research support to institution.Speaker for AVEO Pharmaceuticals, Inc.; Bayer Corporation; BIO Brazilian Information Oncology; Exelixis, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Natera, Inc.; OLE Forum (Mexico); and Seagen Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XJV865. CME/MOC/AAPA credit will be available until December 28, 2024.Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerSia Daneshmand, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ferring Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Pacific Edge; Pfizer; Photocure; Protara Therapeutics, Inc.; Sesen Bio (Carisma Therapeutics); TARIS Biomedical; and UroGen.Grant/Research Support from Janssen Pharmaceuticals, Inc.Faculty/PlannerGuru P. Sonpavde, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bicycle Therapeutics; Bristol Myers Squibb; EMD Serono Inc.; Ellipses Pharma; Exelixis, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Infinity Pharmaceuticals, Inc.; IMV Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; Lucence Health Inc.; Merck & Co., Inc.; Pfizer; PRECISCA; Sanofi; Scholar Rock; Seattle Genetics (Seagen Inc.)/Astellas Pharma Inc.; Servier Laboratories; SUBA THERAPEUTICS, INC.; Syapse; Syncorp Health; Tempus; and Vial.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; EMD Serono Inc.; Gilead Sciences, Inc.; Helsinn Healthcare SA; Jazz Pharmaceuticals; Lucence; and Sanofi. Research support to institution.Speaker for AVEO Pharmaceuticals, Inc.; Bayer Corporation; BIO Brazilian Information Oncology; Exelixis, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Natera, Inc.; OLE Forum (Mexico); and Seagen Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XJV865. CME/MOC/AAPA credit will be available until December 28, 2024.Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerSia Daneshmand, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ferring Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Pacific Edge; Pfizer; Photocure; Protara Therapeutics, Inc.; Sesen Bio (Carisma Therapeutics); TARIS Biomedical; and UroGen.Grant/Research Support from Janssen Pharmaceuticals, Inc.Faculty/PlannerGuru P. Sonpavde, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bicycle Therapeutics; Bristol Myers Squibb; EMD Serono Inc.; Ellipses Pharma; Exelixis, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Infinity Pharmaceuticals, Inc.; IMV Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; Lucence Health Inc.; Merck & Co., Inc.; Pfizer; PRECISCA; Sanofi; Scholar Rock; Seattle Genetics (Seagen Inc.)/Astellas Pharma Inc.; Servier Laboratories; SUBA THERAPEUTICS, INC.; Syapse; Syncorp Health; Tempus; and Vial.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; EMD Serono Inc.; Gilead Sciences, Inc.; Helsinn Healthcare SA; Jazz Pharmaceuticals; Lucence; and Sanofi. Research support to institution.Speaker for AVEO Pharmaceuticals, Inc.; Bayer Corporation; BIO Brazilian Information Oncology; Exelixis, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Natera, Inc.; OLE Forum (Mexico); and Seagen Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XJV865. CME/MOC/AAPA credit will be available until December 28, 2024.Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerSia Daneshmand, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ferring Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Pacific Edge; Pfizer; Photocure; Protara Therapeutics, Inc.; Sesen Bio (Carisma Therapeutics); TARIS Biomedical; and UroGen.Grant/Research Support from Janssen Pharmaceuticals, Inc.Faculty/PlannerGuru P. Sonpavde, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bicycle Therapeutics; Bristol Myers Squibb; EMD Serono Inc.; Ellipses Pharma; Exelixis, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Infinity Pharmaceuticals, Inc.; IMV Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; Lucence Health Inc.; Merck & Co., Inc.; Pfizer; PRECISCA; Sanofi; Scholar Rock; Seattle Genetics (Seagen Inc.)/Astellas Pharma Inc.; Servier Laboratories; SUBA THERAPEUTICS, INC.; Syapse; Syncorp Health; Tempus; and Vial.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; EMD Serono Inc.; Gilead Sciences, Inc.; Helsinn Healthcare SA; Jazz Pharmaceuticals; Lucence; and Sanofi. Research support to institution.Speaker for AVEO Pharmaceuticals, Inc.; Bayer Corporation; BIO Brazilian Information Oncology; Exelixis, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Natera, Inc.; OLE Forum (Mexico); and Seagen Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/UAR865. CME/MOC/AAPA credit will be available until December 31, 2024.Under Pressure to Improve Prostate Cancer Care: Unlocking the Power of Advanced Therapeutics to Enhance Outcomes Across the Disease Continuum In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical educational grants from Astellas and Pfizer, Inc., AstraZeneca, Exelixis, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lilly, Merck & Co., Inc., and Novartis Pharmaceuticals Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerAlicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.Faculty/PlannerAshley E. Ross, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; BillionToOne Inc.; Blue Earth Therapeutics; and Janssen Pharmaceuticals, Inc.Grant/Research Support from Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; Blue Earth Therapeutics; and Lantheus.Speakers Bureau participant with Bayer HealthCare Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Blue Earth Therapeutics; Lantheus; and Veracyte, Inc.Faculty/PlannerMatthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ambrx; Astellas Pharma US, Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/UAR865. CME/MOC/AAPA credit will be available until December 31, 2024.Under Pressure to Improve Prostate Cancer Care: Unlocking the Power of Advanced Therapeutics to Enhance Outcomes Across the Disease Continuum In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical educational grants from Astellas and Pfizer, Inc., AstraZeneca, Exelixis, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lilly, Merck & Co., Inc., and Novartis Pharmaceuticals Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerAlicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.Faculty/PlannerAshley E. Ross, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; BillionToOne Inc.; Blue Earth Therapeutics; and Janssen Pharmaceuticals, Inc.Grant/Research Support from Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; Blue Earth Therapeutics; and Lantheus.Speakers Bureau participant with Bayer HealthCare Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Blue Earth Therapeutics; Lantheus; and Veracyte, Inc.Faculty/PlannerMatthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ambrx; Astellas Pharma US, Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/UAR865. CME/MOC/AAPA credit will be available until December 31, 2024.Under Pressure to Improve Prostate Cancer Care: Unlocking the Power of Advanced Therapeutics to Enhance Outcomes Across the Disease Continuum In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical educational grants from Astellas and Pfizer, Inc., AstraZeneca, Exelixis, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lilly, Merck & Co., Inc., and Novartis Pharmaceuticals Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerAlicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.Faculty/PlannerAshley E. Ross, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; BillionToOne Inc.; Blue Earth Therapeutics; and Janssen Pharmaceuticals, Inc.Grant/Research Support from Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; Blue Earth Therapeutics; and Lantheus.Speakers Bureau participant with Bayer HealthCare Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Blue Earth Therapeutics; Lantheus; and Veracyte, Inc.Faculty/PlannerMatthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ambrx; Astellas Pharma US, Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/UAR865. CME/MOC/AAPA credit will be available until December 31, 2024.Under Pressure to Improve Prostate Cancer Care: Unlocking the Power of Advanced Therapeutics to Enhance Outcomes Across the Disease Continuum In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical educational grants from Astellas and Pfizer, Inc., AstraZeneca, Exelixis, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lilly, Merck & Co., Inc., and Novartis Pharmaceuticals Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerAlicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.Faculty/PlannerAshley E. Ross, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; BillionToOne Inc.; Blue Earth Therapeutics; and Janssen Pharmaceuticals, Inc.Grant/Research Support from Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; Blue Earth Therapeutics; and Lantheus.Speakers Bureau participant with Bayer HealthCare Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Blue Earth Therapeutics; Lantheus; and Veracyte, Inc.Faculty/PlannerMatthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ambrx; Astellas Pharma US, Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/UAR865. CME/MOC/AAPA credit will be available until December 31, 2024.Under Pressure to Improve Prostate Cancer Care: Unlocking the Power of Advanced Therapeutics to Enhance Outcomes Across the Disease Continuum In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical educational grants from Astellas and Pfizer, Inc., AstraZeneca, Exelixis, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lilly, Merck & Co., Inc., and Novartis Pharmaceuticals Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerAlicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.Faculty/PlannerAshley E. Ross, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; BillionToOne Inc.; Blue Earth Therapeutics; and Janssen Pharmaceuticals, Inc.Grant/Research Support from Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; Blue Earth Therapeutics; and Lantheus.Speakers Bureau participant with Bayer HealthCare Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Blue Earth Therapeutics; Lantheus; and Veracyte, Inc.Faculty/PlannerMatthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ambrx; Astellas Pharma US, Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/UAR865. CME/MOC/AAPA credit will be available until December 31, 2024.Under Pressure to Improve Prostate Cancer Care: Unlocking the Power of Advanced Therapeutics to Enhance Outcomes Across the Disease Continuum In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical educational grants from Astellas and Pfizer, Inc., AstraZeneca, Exelixis, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lilly, Merck & Co., Inc., and Novartis Pharmaceuticals Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerAlicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.Faculty/PlannerAshley E. Ross, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; BillionToOne Inc.; Blue Earth Therapeutics; and Janssen Pharmaceuticals, Inc.Grant/Research Support from Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; Blue Earth Therapeutics; and Lantheus.Speakers Bureau participant with Bayer HealthCare Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Blue Earth Therapeutics; Lantheus; and Veracyte, Inc.Faculty/PlannerMatthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ambrx; Astellas Pharma US, Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/UAR865. CME/MOC/AAPA credit will be available until December 31, 2024.Under Pressure to Improve Prostate Cancer Care: Unlocking the Power of Advanced Therapeutics to Enhance Outcomes Across the Disease Continuum In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical educational grants from Astellas and Pfizer, Inc., AstraZeneca, Exelixis, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lilly, Merck & Co., Inc., and Novartis Pharmaceuticals Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerAlicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.Faculty/PlannerAshley E. Ross, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; BillionToOne Inc.; Blue Earth Therapeutics; and Janssen Pharmaceuticals, Inc.Grant/Research Support from Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; Blue Earth Therapeutics; and Lantheus.Speakers Bureau participant with Bayer HealthCare Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Blue Earth Therapeutics; Lantheus; and Veracyte, Inc.Faculty/PlannerMatthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ambrx; Astellas Pharma US, Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/UAR865. CME/MOC/AAPA credit will be available until December 31, 2024.Under Pressure to Improve Prostate Cancer Care: Unlocking the Power of Advanced Therapeutics to Enhance Outcomes Across the Disease Continuum In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical educational grants from Astellas and Pfizer, Inc., AstraZeneca, Exelixis, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lilly, Merck & Co., Inc., and Novartis Pharmaceuticals Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNeal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.Faculty/PlannerAlicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.Faculty/PlannerAshley E. Ross, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; BillionToOne Inc.; Blue Earth Therapeutics; and Janssen Pharmaceuticals, Inc.Grant/Research Support from Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; Blue Earth Therapeutics; and Lantheus.Speakers Bureau participant with Bayer HealthCare Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Blue Earth Therapeutics; Lantheus; and Veracyte, Inc.Faculty/PlannerMatthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Ambrx; Astellas Pharma US, Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

In just over two years, Everyday Anarchism hits 100 episodes!Kim Stanley Robinson returns to discuss The Pacific Edge, the third volume of his Three Californias triptych. We discuss how the beautiful ecosocialist utopia in The Pacific Edge keeps all of the mundanity, tedium, and tragedy of life, just without the horrors of neoliberal capitalism. Stan also explains why he's unsatisfied with the book - and how that led him to writing his Mars trilogy, which we'll discuss in depth in 2024!This series of episodes is dedicated to Dr. Robert Corbin: teacher, mentor, friend, and, above all, rebel with a cause.

Kim Stanley Robinson and I discuss The Gold Coast, the second volume of his Three Californias triptych. We discuss how the Reagan era served as the inspiration for the book, the connection between the character Dennis McPherson and Stan's own father, and why this is Stan's favorite of the trilogy.Join us next month for a discussion of the final volume of the triptych, The Pacific Edge

Pacific Edge CEO Dr Peter Meintjes joins Sharesies General Manager of company partnerships Susannah Batley for a quick update on Pacific Edge's recent results. Plus, an update on Novitas coverage of Pacific Edge's Cxbladder tests, which could impact Medicare eligibility in the US. For more or to watch on youtube—check out http://linktr.ee/sharedlunch A conversation with experts, CEOs, and you. We talk to company leaders and industry experts every week. Listen or watch over lunch or whenever you want to snack on what's happening in the economy, the markets, and the companies you invest in. Brought to you by Sharesies, with BusinessDesk. Appearance on Shared Lunch is not an endorsement by Sharesies of the views of the presenters, guests, or the entities they represent. Their views are their own. Shared Lunch is not financial advice. We recommend talking to a licensed financial adviser. You should review relevant product disclosure documents before deciding to invest. Investing involves risk. You might lose the money you start with. Content is current at the time. Shared Lunch is for a New Zealand audience.

Manda Aufochs Gillespie/ Folk U - Learn some of the stories of the biodiversity and resilience on the Pacific Edge as author and Hakai Institute chronicler, Tyee Bridge joins host Manda Aufochs Gillespie Friday at 1 p.m. to discuss the research and writing of Heart of the Coast. Learn more about this region in Deep Time, the archeology and geology, all the way to present day sea stars and kelp to subsidies, science, and students. And do you know how many viruses can be found in seawater? Learn all this and more.

Pfizer (PFE) and BioNTech (BNTX) say that preliminary data shows a third dose of their COVID-19 vaccine improves protection against Omicron. EBOS (EBO) Group inks a deal to acquire medical equipment distributor LifeHealthcare Cancer. Pacific Edge (PEB) signs its first commercial deal of scale in Australia. www.sharesies.com For more share market news, subscribe to Lunch Money, Sharesies' bite-sized email update: https://www.sharesies.nz/lunch-money If you'd like to get in touch, for any reason at all, email recap@sharesies.co.nz or record a voice message: https://anchor.fm/sharesies2/message. Investing involves risk. You aren't guaranteed to make money, and you might lose the money you start with. We don't provide personalised advice or recommendations. Any information we provide is general only and current at the time. For specific advice, speak to a licensed financial advice provider

Pacific Edge: Now this is clever; a non-invasive way to detect & manage bladder cancer Listen to ASX-listed Pacific Edge Ltd Executive Director David Darling talk to Matt Birney on the Bulls N' Bears Report about the company's 100 per cent increase in annual sales for its fascinating medical technology. See omnystudio.com/listener for privacy information.

Cancer-diagnostics company Pacific Edge (PEB) lists on the Australian Securities Exchange (ASX), as well as announcing a capital raise. Dairy giant Fonterra (FSF) releases its full-year results, impacted by high milk prices. Netflix (NFLX) announces it's acquiring the company of children's author Roald Dahl. Also we have updates on the Federal Reserve's announcement and Coinbase's dealings with the SEC. www.sharesies.com For more share market news, subscribe to Lunch Money, Sharesies' bite-sized email update: https://www.sharesies.nz/lunch-money If you'd like to get in touch, for any reason at all, email recap@sharesies.co.nz or record a voice message: https://anchor.fm/sharesies2/message. Investing involves risk. You aren't guaranteed to make money, and you might lose the money you start with. We don't provide personalised advice or recommendations. Any information we provide is general only and current at the time. For specific advice, speak to a licensed financial advice provider

Pacific Edge (PEB) gives an update on Q1, reporting growth in sales for its Cxbladder tests. Facebook (FB) releases its latest earnings and gives insight on the company's future. Wesfarmers' (WES) takeover bid gets rejected by Australian Pharmaceutical Industries (API). www.sharesies.com Pacific Edge CEO David Darling on Lunch Money For more share market news, subscribe to Lunch Money, Sharesies' bite-sized email update: https://www.sharesies.nz/lunch-money Investing involves risk. You aren't guaranteed to make money, and you might lose the money you start with. We don't provide personalised advice or recommendations. Any information we provide is general only and current at the time.

This week on Lunch Money, Leighton Roberts (Sharesies' Co-Founder) and Alice Rountree (Sharesies' Financial Analyst) catch up with David Darling, the CEO of Pacific Edge. Pacific Edge is a Dunedin-based company that's listed on the NZX, and specialises in developing cancer diagnostic tests. David talks us through the fascinating history of this life saving company, an overview of products and the markets they operate in and what is the future for David now he's stepping away from the company after 20 years. If you have any questions, email us at any time at help@sharesies.co.nz. If there are any companies, fund managers, or other special guests you'd like to see on Lunch Money going forward, flick us an email at events@sharesies.co.nz to let us know! For more market news, subscribe to our Lunch Money market updates—bite-sized emails on the New Zealand, Australian, and US share markets and the wider economy, written by Sharesies' Lead Dealer, Sophie Goodwin: https://www.sharesies.nz/lunch-money

After 12 years, Luke finally reads the third book of Kim Stanley Robinson’s Three Californias Triptych: Pacific Edge. Get this audiobook for free, or any of 100,000 other titles, as part of a free trial by visiting this link: https://www.audibletrial.com/sfbrp. Buy this book at , or discuss this book at Goodreads.com Luke blogs at: https://www.lukeburrage.com/blog […]

About the Guest Ed Asner has been an enduring presence in television, film and stage for 60 years. Developing his craft in Chicago and New York, Ed established himself as a solid and versatile performer, regularly featured in roles on the big screen and in such landmark television series as “The Outer Limits”, “Gunsmoke”, “The Wild Wild West”, “Ironside”, and “Mission Impossible”, totaling more than 100 television credits. In the ’70s, his role as Lou Grant in the long-running hit sitcom “The Mary Tyler Moore Show” catapulted him to stardom. He then cemented himself as an “actor’s actor”, perpetuating his character in the dramatic series “Lou Grant”. Asner is the only actor to have won an Emmy for the same role in both a comedy and a drama (five total as Lou Grant). He went on to win two more Emmy Awards for complex roles in the mega-hit miniseries “Roots” and “Rich Man, Poor Man”. In addition to his celebrated work in television, he turned in unforgettable performances in films such as “JFK”, “Elf”, and “Pacific Edge”. He returned to Broadway in “Grace”, and toured the country with his one-man show “FDR”, portraying President Franklin D. Roosevelt. He also served two terms as President of the Screen Actors Guild, protecting the rights of professional working actors. For more information visit: http://www.amanandhisprostate.com/ (http://www.amanandhisprostate.com/) https://www.templeshows.com/ (https://www.templeshows.com/) https://edasnerfamilycenter.org/ (https://edasnerfamilycenter.org/) Connect with Us Facebook – @rduonstage Twitter – @rduonstage Instagram – @rduonstage Web http://www.rduonstage.com/ (www.rduonstage.com) Support this podcast

An episode of diary entries — Sunday, 20 September 2020 — 12:05 p.m. — “The Song of the Volga Boatmen” — The emotional arc of waking up on some days — A feature of art — Emotional underpinnings — 12:22 p.m. — Norm Macdonald video of Letterman appearances — “Calypso Blues” by Nat King Cole (music) & Don George (lyrics) — A song that can bring a smile — Version by Mona Baptiste (early 1950s) — Sultry, interesting, relaxed — 23 September, 12:31 a.m. — Rod Serling talking to a group of young writers — Norm Macdonald's comment on The Twilight Zone — Probably the best TV series of all time — If only one TV series could survive — Only the original series — A series that gives you something — Alienation, loneliness, times of feeling lost in life, etc. — Dark in a healthy, helpful way — Northern Exposure — Anyone who watches it will benefit from the experience — The opposite of heavy — Back to The Twilight Zone — The dark gem — Should play in all countries at odd hours — Always swimming in our collective electrical subconscious — A pure, clarifying anger — Rod Serling cared — Genuine mystery and imagination — A sense of theatre — Virtually all science fiction series try to be multimillion-dollar films — The real gold of the future — The virtues of theatre — Most creators of science fiction, horror, or fantasy have no sense of imagination and mystery — David Lynch was right — Mystery is no longer appreciated — It can bring any type of story alive — Things that won't — Mystery, imagination, heart, and magic — 7 October 2020, 8:31 p.m. — Long pause — Even one great song — Songwriting — There had never been a song like “Riders in the Sky” — The kernel from which Ennio Morricone unfolded his western music — A reminder about life — Now is the only time — Quote from Kim Stanley Robinson's Pacific Edge (1988, from the Three Californias Trilogy) — “What do you talk about when you're falling in love?” — When the apocalypse comes — Its own paradise — We don't get everything — Fate is a strange thing

Mainfreight shares hit a record $46.95 in early trading following a strong update and upbeat annual meeting. The shares rose 19% this month, valuing the business at $4.7 billion. Jarden analysts said the result was "remarkable" and upgraded their forecast for net profit in the March 2021 year by 25%, due to increasing revenue in Australia and NZ. Mainfreight reported growth in revenue of 5% and profit before tax growth of 18% for the first 4 months of this financial year which covered the lockdown. The only downside to the update was the reduction in revenue growth in the Americas. Pacific Edge rose a further 177%, extending an ongoing surge which has seen it gain more than 525% year to date. Recently ANZ's funds management arm bought $22 million of new shares in Pacific Edge, not long after the company was approved to provide services under the United States' national health insurance schemes. The market is continuing to get its head around the market size in the US and what the potential income streams could be. Marketing tech specialist Plexure announced it is looking at changing its primary listing to the ASX to have better access to capital. Shares rose 59%. Communications and power infrastructure company ikeGPS said it will raise almost $20 million of new equity after winning one of the largest communications infrastructure companies in the United States as a customer. It will also use the money for potential growth opportunities and take on new staff. ikeGPS up 24%after its institutional placement closed oversubscribed. Existing shareholders can subscribe for one share for every seven they own. New shares will be issued at a price of $0.68 a share, which represents a 11.7% discount to the last closing price of $0.77. ✅ Learn other tips at https://www.MaximSherstobitov.NZ/

Z Energy rose 7.66% because it increased the market share. The first quarter results for their 2021 financial year, although poor compared to last year, were above market expectations. The report covered Z's performance between March 31 and June 30, encompassing most of the alert level 4 lockdown. Total revenue was $594 million, down 53 per cent from last year's $1257m. This was primarily because lockdown reduced fuel sales by 39 per cent. As expected, jet fuel was hit the hardest: volumes were 53 per cent lower than last year. Volumes in the less-impacted diesel sector dropped by 19.5 per cent, and petrol volumes were down 40.8 per cent. Cost-saving procedures meant Z's statutory loss for the quarter was limited to $49m. Pacific Edge gained 23.1% after ANZ New Zealand Investments bought $22 million of new shares at a 14% premium. The stock is up 475% year-to-date and may be next in line to join the index. Cavalier Corp rose 28.57%. The wool and carpet company said stock levels had decreased "significantly" to about $35 million, on the back of "stronger than anticipated" trading through June, particularly in wool sales. Cannasouth went up 12.12% after announcing a new joint venture with Vera Cultivation, a Colorado-based, market-leading cannabis producer. Vera will help Cannasouth design their cultivation facility, develop licensed operating systems and procedures, and provide support for implementation of growing facilities over the next 30 months. ✅ Learn other tips at https://www.MaximSherstobitov.NZ/

In this episode, XPRIZE founder Peter H. Diamandis discusses AI and how it is often portrayed in science fiction with world renowned sci-fi author Kim Stanley Robinson, at XPRIZE Visioneering recorded at Paramount Studios. Robinson questions our relationship with AI and the important future of synthetic medicine. Although he is inspired by space exploration, he argues that the race to Mars is not an urgent problem, but rather a reward for fixing the problems on planet Earth. Recently named by Fortune as one of the “World’s 50 Greatest Leaders,” Peter H. Diamandis is the founder and executive chairman of the XPRIZE Foundation, which leads the world in designing and operating large-scale incentive competitions. He is also the executive founder of Singularity University, a graduate-level Silicon Valley institution that counsels the world's leaders on exponentially growing technologies. As an entrepreneur, Diamandis has started over 20 companies in the areas of longevity, space, venture capital and education. He is cofounder of BOLD Capital Partners, a venture fund with $250M investing in exponential technologies, and co-founder and Vice Chairman of Celularity, Inc., a cellular therapeutics company. Diamandis is a New York Times Bestselling author of two books: Abundance – The Future Is Better Than You Think and BOLD – How to go Big, Create Wealth & Impact the World. His newest book in this series of exponential technologies—The Future is Faster Than You Think—was released on January 28, 2020. He earned degrees in molecular genetics and aerospace engineering from the MIT and holds an M.D. from Harvard Medical School. Diamandis’ favorite saying is “the best way to predict the future is to create it yourself.”Kim Stanley Robinson is an American novelist, widely recognized as one of the foremost living writers of science fiction. Robinson began publishing novels in 1984. His work has been described as "humanist science fiction" and "literary science fiction". Robinson himself has been a proud defender and advocate of science fiction as a genre, which he regards as one of the most powerful of all literary forms.Robinson was born in Waukegan, Illinois, but moved to Orange County, California, when he was two. As a child he loved to play in the orange groves stretching out for miles around his home, so when suburban sprawl began to encroach and the groves were torn out and paved over, the rapid change of modern life hit close to home. It was not until college in 1971 that he would stumble upon new wave science fiction and find in it an expression of that very sense of rapid change that had made such an impression upon him growing up, at which point he knew almost immediately that he would be committed to science fiction from then on. He enrolled at the University of California-San Diego (UCSD) in 1970 and received his B.A. in Literature in 1974. During that time he developed the idea to write a trio of books exploring three different alternative future histories in which southern California had gone down different paths, what became the Orange County trilogy. After briefly leaving California to receive an M.A. in English at Boston University in 1975, Robinson returned to UCSD to complete his Ph.D. Though science fiction was something of a "literary ghetto culture" in the academic world, Robinson could not have had a more sympathetic advisor in Fredric Jameson, who suggested that Robinson do his thesis on the works of Philip K. Dick, whom Robinson was not particularly familiar with at the time but whom Jameson regarded as the greatest living American novelist. Robinson agreed to the idea and finished his Ph.D. in 1982, a revised version of which was published in 1984 as The Novels Of Philip K. Dick. In 1978 Robinson took a break from his Ph.D. work and moved north to Davis, California, where he worked in a bookstore and spent a lot of time outdoors, especially backpacking in the mountains, where he continued to develop his love for landscape and the outdoors. While in Davis he met Lisa Howland Nowell, an environmental chemist, and in 1982 upon completing his Ph.D. he returned to Davis and the two were married. He taught freshman composition among other courses at UC Davis, another autobiographical tidbit that would be bestowed upon his fictional alter-ego Jim in 1988's The Gold Coast. Then a few years later, after publishing his first few novels, his wife's post-doctoral work in environmental toxicology took the couple to Switzerland, where they lived for two years, and at which point he began to write full time. Her work also took them to Washington, D.C., and during their four years there Robinson was a stay-at-home parent to their first son while his wife worked. Finally, in 1991 they moved back to Davis to buy a house in Village Homes -- a planned community that shares many things in common with the community depicted in his 1990 novel Pacific Edge -- where their second son was born. Robinson is still the stay-at-home parent, giving him plenty of time to write, while his wife continues to work full time as a chemist. As a result, much of the couple's social circle is made up of her friends and colleagues, giving Robinson ample material with which to write about scientists. As can be gathered from above, Robinson enjoys inserting personal life experiences or autobiographical elements in his works. For example:Robinson enjoys mountaineering greatly, which can be seen in landscape descriptions and trekking trips in nearly all his works.His stay in Switzerland is a likely inspiration for frequent references to Swiss government and people (Green Mars, Fifty Degrees Below).He has visited Greece and enjoys the architecture of the Greek islands (The Gold Coast, Blue Mars).He likes softball, referenced in Icehenge and Pacific Edge, and plays the frisbee golf described in Fifty Degrees Below.At times he is a stay-at-home dad, like Charlie Quibler in the Science In The Capital trilogy.He is a Californian teacher, like characters in The Gold Coast and The Years Of Rice And Salt.Links: https://www.kimstanleyrobinson.info See acast.com/privacy for privacy and opt-out information.

If you want to find out more information about the podcast go to www.stockmarketmovers.co.nz, make sure that you also check out the blog posts. Disclaimer: As always, nothing that is discussed in the podcast is financial advice. If you are looking for financial advice please contact an authorised financial adviser.

Our discussion of Pacific Edge by Kim Stanley Robinson covers a plot summary and explores what our future can look like through this utopian eco fiction novel. Transcript: https://storiesforearth.com/2020/02/24/pacific-edge-kim-stanley-robinson/ Support us on Patreon: https://www.patreon.com/storiesforearth

This week, Liberty and Rebecca discuss Upright Women Wanted, Black Sunday, The Toni Morrison Book Club, and more great books. This episode was sponsored by The Handell; Me and White Supremacy: Combat Racism, Change the World, and Become a Good Ancestor by Layla Saad; and Book Riot Insiders. Pick up an All the Books! 200th episode commemorative item here. Subscribe to All the Books! using RSS, iTunes, or Spotify and never miss a beat book. Sign up for the weekly New Books! newsletter for even more new book news. BOOKS DISCUSSED ON THE SHOW: Upright Women Wanted by Sarah Gailey Me and White Supremacy: Combat Racism, Change the World, and Become a Good Ancestor by Layla Saad Things in Jars by Jess Kidd Heathcliff Redux: A Novella and Stories by Lily Tuck Black Sunday: A Novel by Tola Rotimi Abraham The Toni Morrison Book Club by Juda Bennett, Winnifred Brown-Glaude, Casssandra Jackson, Piper Kendrix Williams My Autobiography of Carson McCullers: A Memoir by Jenn Shapland How to Do Nothing: Resisting the Attention Economy by Jenny Odell WHAT WE’RE READING: Kitchen Confidential Updated Edition: Adventures in the Culinary Underbelly (P.S.) by Anthony Bourdain Deeplight by Frances Hardinge MORE BOOKS OUT THIS WEEK: The King of Crows by Libba Bray The Blue Absolute by Aaron Shurin Things Seen from Above by Shelley Pearsall My Name Is Why: A Memoir by Lemn Sissay Noisemakers: 25 Women Who Raised Their Voices & Changed the World – A Graphic Collection from Kazoo by Kazoo Magazine Race Against Time: A Reporter Reopens the Unsolved Murder Cases of the Civil Rights Era by Jerry Mitchell A Blight of Blackwings (The Seven Kennings) by Kevin Hearne The Force of Nonviolence: The Ethical in the Political by Judith Butler The Willies by Adam Falkner A Divided Loyalty: A Novel (Inspector Ian Rutledge Mysteries Book 22) by Charles Todd Black Imagination: Black Voices on Black Futures by Natasha Marin Race Man: Selected Works, 1960-2015 by Julian Bond, Michael G. Long The Convert: A Novel by Stefan Hertmans, David McKay (translator) Behind Every Lie by Christina McDonald Three Californias: The Wild Shore, The Gold Coast, and Pacific Edge by Kim Stanley Robinson Parked by Danielle Svetcov The Wrong Kind of Women: Inside Our Revolution to Dismantle the Gods of Hollywood by Naomi McDougall Jones Calamity: The Many Lives of Calamity Jane by Karen R. Jones Belle Revolte by Linsey Miller Malice by Pintip Dunn Itch by Polly Farquhar The Impossible First: From Fire to Ice-Crossing Antarctica Alone by Colin O’Brady The Big Goodbye: Chinatown and the Last Years of Hollywood by Sam Wasson What Kind of Girl by Alyssa Sheinmel Open Book by Jessica Simpson A Perfect Explanation by Eleanor Anstruther Ember Queen (Ash Princess) by Laura Sebastian Smacked: A Story of White-Collar Ambition, Addiction, and Tragedy by Eilene Zimmerman Remembered by Yvonne Battle-Felton Straight On Till Morning: A Twisted Tale by Liz Braswell How to Overcome Your Childhood by The School of Life by Alain de Botton The Way Home (Owly 1) Andy Runton Promises of the Heart: A Novel (Savannah Skies Book 1) by Nan Rossiter Chirp by Kate Messner Romance or the End: Poems by Elaine Kahn Alice By Heart by Steven Sater Home Games by Benjamin Markovits What Is Time to a Pig? by John Straley Rough Ideas: Reflections on Music and More by Stephen Hough Minor Dramas & Other Catastrophes by Kathleen West The Scientist and the Spy: A True Story of China, the FBI, and Industrial Espionage by Mara Hvistendahl Dressed for a Dance in the Snow: Women’s Voices from the Gulag by Monika Zgustova, Julie Jones (translator) The Misfortunes of Family by Meg Little Reilly Mindy Kim and the Yummy Seaweed Business (1) by Lyla Lee and Dung Ho Self-Care Down There: From Menstrual Cups and Moisturizers to Body Positivity and Brazilian Wax, a Guide to Your Vagina’s Well-Being by Taq Kaur Bhandal Crooked River (Agent Pendergast) by Douglas Preston, Lincoln Child Unfinished Business: Notes of a Chronic Re-reader by Vivian Gornick Alone in the Wild: A Rockton Novel (Casey Duncan Novels Book 5) by Kelley Armstrong The Resisters: A novel by Gish Jen A Black Women’s History of the United States by Daina Ramey Berry and Kali Nicole Gross The Kissing Game by Marie Harte We Had to Be Brave: Escaping the Nazis on the Kindertransport (Scholastic Focus) by Deborah Hopkinson The Museum of Desire: An Alex Delaware Novel by Jonathan Kellerman You Never Forget Your First: A Biography of George Washington by Alexis Coe Mazes of Power (The Broken Trust) by Juliette Wade Djinn Patrol on the Purple Line: A Novel by Deepa Anappara The Queen V: Everything You Need to Know About Sex, Intimacy, and Down There Health Care by Dr. Jackie Walters The Cactus League: A Novel by Emily Nemens Lux by Elizabeth Cook Half Broke: A Memoir by Ginger Gaffney Together We Caught Fire by Eva V. Gibson Disfigured: On Fairy Tales, Disability, and Making Space (Exploded Views) by Amanda Leduc The Freedom Artist by Ben Okri Yes No Maybe So by Becky Albertalli and Aisha Saeed The Killing Tide: A Brittany Mystery (Brittany Mystery Series Book 5) by Jean-Luc Bannalec Brother & Sister: A Memoir by Diane Keaton trans(re)lating house one by Poupeh Missaghi 18 Tiny Deaths: The Untold Story of Frances Glessner Lee and the Invention of Modern Forensics by Bruce Goldfarb Nairobi Noir (Akashic Noir Series) by Peter Kimani Deathless Divide by Justina Ireland All the Stars and Teeth by Adalyn Grace The Gravity of Us by Phil Stamper Valkyrie: Jane Foster, Vol. 1: The Sacred and the Profane by Jason Aaron and Al Ewing Everywhere You Don’t Belong by Gabriel Bump The Lost Book of Adana Moreau: A Novel by Michael Zapata A Heart of Blood and Ashes (A Gathering of Dragons) by Milla Vane The Firmament of Flame (The Universe After Book 3) by Drew Williams The Queen’s Assassin by Melissa de la Cruz Cracked Up to Be by Courtney Summers The Coldest Warrior: A Novel by Paul Vidich I Will Take the Answer: Essays by Ander Monson The Gnome Stories by Ander Monson The Regrets by Amy Bonnaffons King and the Dragonflies by Kacen Callender Verge: Stories by Lidia Yuknavitch Snapdragon by Kat Leyh Olympic Pride, American Prejudice: The Untold Story of 18 African Americans Who Defied Jim Crow and Adolf Hitler to Compete in the 1936 Berlin Olympics by Deborah Riley Draper, Blair Underwood, Travis Thrasher The Third to Die by Allison Brennan Survival Is a Style: Poems by Christian Wiman Real Life by Adeline Dieudonne, Roland Glasser (translator) The Authenticity Project: A Novel by Clare Pooley Molly Bit: A Novel by Dan Bevacqua The Worst Best Man: A Novel by Mia Sosa The Town by Shaun Prescott Stop Telling Women to Smile: Stories of Street Harassment and How We’re Taking Back Our Power by Tatyana Fazlalizadeh The Professor and the Parson: A Story of Desire, Deceit, and Defrocking by Adam Sisman Here in the Real World by Sara Pennypacker When My Time Comes: Conversations About Whether Those Who Are Dying Should Have the Right to Determine When Life Should End by Diane Rehm The Stars We Steal by Alexa Donne A Woman Like Her: The Story Behind the Honor Killing of a Social Media Star by Sanam Maher Perfect Little Children: A Novel by Sophie Hannah The Light After the War: A Novel by Anita Abriel The Legend of the Fire Princess (She-Ra Graphic Novel) by Gigi D.G., Noelle Stevenson A Good Girl’s Guide to Murder by Holly Jackson Vera Violet: A Novel by Melissa Anne Peterson What I Want You To See by Catherine Linka Arlo Finch in the Kingdom of Shadows by John August The Last Day: A Novel by Andrew Hunter Murray I Am a Promise by Shelly Ann Fraser Pryce, Rachel Moss The Only Woman in the Photo: Frances Perkins & Her New Deal for America by Kathleen Krull, Alexandra Bye Toffee by Sarah Crossan Swimming in the Dark: A Novel by Tomasz Jedrowski Run, Rebel by Manjeet Mann Deadland (DS Alexandra Cupidi) by William Shaw Takes One To Know One by Susan Isaacs Escape Routes by Naomi Ishiguro

Like what you see? Please give generously. http://www.thinktechhawaii.com Beyond Magazines. We talked with Naomi about why she founded Pacific Edge Magazine and her challenges as an entrepreneur. The host for this episode is Rusty Komori.

And we are back folks!! After a few weeks of pure chaos we are back with our good friend Joe DeJohn! Joe is a rep for Pacific Edge and oh man is he a character! Joe is so full of engery and life that there's not a dull moment in this one!!

Kauai native Naomi Hazelton is the Publisher and founder of Pacific Edge Magazine, and owner of Element Media Hawaii. This Summer she'll be the navigator in the first ever all-woman team competing in the American Gumball Rally! What does it take to run a publishing company full time, while keeping a full social calendar? Plus why is Pacific Edge one of a few magazines to hold a launch party for each issue? She fills us in on her new project Beyond the Edge aimed at young entrepreneurs. Plus, Flashee Flash plays double duty as bartender making his signature Palomas. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/maleko-and-flash/support

Pacific Edge CEO David Darling on progress with key US customers. Read more ($): https://www.nbr.co.nz/article/pacific-edge-tantalising-close-key-sales-breakthroughs-jr-p-203369

Matt chats with Naomi Hazelton-Giambrone, owner and founder of Element Media. Element produces several local publications, including Pacific Edge magazine. Listen in to understand the ever changing world of creative publishing.  http://www.pacificedgemagazine.com

Episode 020 of the AboutSF podcast is a recording of an interview John C. Tibbetts conducted with science fiction writer Kim Stanley Robinson. If you have not been following the podcasts, John Tibbetts, associate professor in the department of Film and Media Studies at the University of Kansas, provided donations of audio interviews with luminaries in the fields of Science Fiction and Fantasy, including Ray Bradbury, Frederick Pohl and Stephen King, among others, to the J. Wayne and Elsie M. Gunn Center for the Study of Science Fiction in Lawrence, KS. The interviews, gathered during the course of a lifetime of reading, collecting, and writing about Science Fiction, include conversations with Frederick Pohl, Poul Anderson, Jack Williamson, L. Sprague De Camp, and many more. Kim Stanley Robinson is best-known as the author of the Mars trilogy, featuring the landing, exploration, and terraforming of Mars. Many of Robinson's works feature ecological issues, as well as scientific research and how to find balance between technology and human pursuits. He won the Nebula Award for Red Mars, the beginning of the trilogy. Robinson went on to win the Hugo Awards for Green Mars and Blue Mars. He also won the John W. Campbell Memorial Award for Best Science Fiction Novel for Pacific Edge. In this episode, Robinson discusses his research about the planet Mars for his trilogy, his inspiration for writing the novels, and his ambitions for writing science fiction.